This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. It is the third most common cardiovasculardisease [2]. For long lesions, Duo Extend smoothly overlaps with the Duo Hybrid to extend therapy.
Clinical success was defined as optimal stent expansion after final treatment with no in-hospital major adverse cardiovascular event (MACE). stent expansion at Maximum Calcium Site 96.7% interventional cardiologist at ZNA Cardiovascular Center in Antwerp, Belgium. . stent expansion at Maximum Calcium Site 96.7%
v As cardiovasculardisease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. CCTA offers a non-invasive, cost-effective, and highly sensitive method for diagnosing coronary artery disease (CAD), making it a valuable tool for clinicians.
Triglyceride-glucose (TyG) index is an emerging surrogate indicator of insulin resistance, which has been demonstrated as a risk factor for various cardiovasculardiseases including coronary syndrome, in-stent.
FDA Breakthrough Device Designation accelerates the review process for novel technologies that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, such as CAD, which impacts 7.8% Stent Related Adverse Events greater than 1 Year After PCI. of the U.S. population.
Cardiovasculardisease (CVD) remains the leading cause of death in the U.S. This article will explore how AI-driven diagnostics are reshaping cardiovascular medicine and how can healthcare leaders can leverage these innovations to improve patient care and control costs. That future isnt decades away. It is already here.
Within the complex umbrella of cardiovasculardisease, CAD is a type of heart disease that develops when the coronary arteries narrow and the heart cannot deliver enough oxygen-rich blood to the heart.
In a retrospective study of older patients (≥65 years) with cardiovasculardisease who were admitted to a cardiology service, the prevalence of polypharmacy (five or more medications) was 95% and 69% for hyper-polypharmacy (≥10 medications), far exceeding that observed in the general population; 77.5% 2021;374:n1493.
Exercise prevents and reverses cardiovasculardisease, but whether high-intensity exercise training (HIIT) is safe and effective for adults after minimally invasive heart surgery is unknown. Exercise is a wonder drug for cardiovasculardisease (CVD) prevention and reversal.
Cardiovascular Update for the Clinician: A Symposium by Valentin Fuster” will offer the latest advances in the treatment of cardiovasculardisease and ways to integrate them into daily practice. 24 Education Sessions Symposiums at ACC The “Symposiums at ACC.24”
The European Society of Cardiology (ESC) Congress 2024 (August 30 – September 2, 2024) has wrapped up, delivering groundbreaking insights into cardiovasculardiseases and related conditions.
IVL helps restore blood flow by cracking calcium lesions using sonic pressure waves and is used in both CAD and PAD, often in combination with stenting. IVL is a minimally invasive, catheter-based treatment for calcified arterial lesions, which can reduce blood flow and cause pain or heart attack.
IntroductionEmerging evidence suggests a robust association between cardiovasculardisease (CVD) and cognitive decline, accentuating the necessity for early detection and intervention. years, 50% males) at increased risk for cardiovasculardisease (CVD) as assessed by the systematic coronary risk evaluation tool.
All the patients were observed during their hospital stay for postprocedure in-hospital morbidity (pump failure, contrast-induced nephropathy, major bleeding, cerebrovascular accident/stroke, access site complications or stent thrombosis) and mortality. The mean BMI was 27.48±4.93 kg/m 2 and 23.2% (255) were categorised as obese.
Below, we aim to debunk common myths about cardiovasculardisease, providing accurate information and emphasizing the importance of treatment for heart disease with timely interventions. Procedures such as angioplasty, stenting and bypass surgery can restore blood flow to the heart and improve function.
Large-scale observational data have demonstrated a robust, independent association of elevated lipoprotein(a) (Lp[a]) levels with atherosclerotic cardiovasculardisease (CVD), stroke, and peripheral artery disease.
He had no apparent risk factors for cardiovasculardisease. He was successfully treated with one drug eluting stent. Pain largely resolved prior to EMS arrival but completely subsided after prehospital NTG and aspirin. At the time of arrival to the ED, the patient reported 1/10 chest pain with normal vital signs.
There was no premature cardiovasculardiseases or sudden death in his family. The lesion was successfully stented. His medical history is unremarkable except a similar pain occurred 4-5 times in the previous 3 months with less intensity, short duration, unrelated to exertion. He has 40 packs-year of smoking history.
Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovasculardisease (CVD). The primary non-inferiority endpoint was MACCE (a composite of cardiac death, MI, ischaemic stroke, stent thrombosis, or target vessel revascularisation).
This video is not for those patients who have already had a heart attack or a stroke or stents or bypasses or some other form of vascular event who are trying to prevent a further event by taking Aspirin. For those people there exists the Secondary Bank of Aspirin which I shall talk about in a later video.
BackgroundSystemic inflammation plays a vital role in the pathogenesis and prognosis of cardiovasculardisease (CAD). The systemic immune-inflammation index (SII) has been developed as a cost-effective and practical predictor for CAD outcomes.
August 2024 Approvals Minima Stent System (P240003) (Approval Date: August 28, 2024) The Minima Stent System is an expandable cobalt-chromium metal mesh tube to reopen blood vessels in neonates, infants, and children with Coarctation of the Aorta and Pulmonary Artery Stenosis, specifically designed to expand as younger patients grow.
It is asking for stenting all non-flow limiting lesion , if found, to carry high risk plaques by intracoronary Imaging. Top 10 Clinical Trials Preventive PCI on Stenosis With Functionally Insignificant Vulnerable Plaque PREVENT (ACC.24) 24) Microaxial Flow Pump in Infarct-Related Cardiogenic Shock DanGer Shock (ACC.24) Did we follow up ?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content